Patrys Ltd
Patrys Advances RLS-2201 Program with Manufacturing Start and FDA Regulatory Engagement
Patrys kicks off RLS-2201 manufacturing with BioCina and FDA 505(b)(2) engagement, targeting Phase 0 trials in H2 2026.
Patrys releases positive data from deoxymabs study to treat ANCA vasculitis
Patrys (ASX: PAB) has released positive data from pre-clinical studies using deoxymabs PAT-DX1 and PAT-DX3 in animal models of the autoimmune disease anti-neutrophil cytoplasmic antibody (ANCA) vasculitis. The therapeutic antibody development company has previously reported non-clinical results that showed the deoxymabs can suppress the formation of neutrophil extracellular traps (NETs), which are structures comprised of […]
Patrys granted Australian patent for Deoxymab platform with nanoparticles to deliver anti-cancer drugs
Therapeutic antibody development company Patrys (ASX: PAB) has been granted an Australian patent covering the use of its novel Deoxymab platform conjugated to nanoparticles (NP) for the targeted delivery of anti-cancer drugs. The patent is the first of its kind for the local market and covers the use of Deoxymab antibodies PAT-DX1 and PAT-DX3 with […]
Patrys’ lead drug candidate can cross blood brain barrier to target triple-negative breast cancers
A pre-clinical animal study by Australian therapeutic antibody company Patrys (ASX: PAB) has shown the development drug PAT-DX1-NP is able to cross the blood brain barrier and successfully target triple-negative breast cancer brain metastases. The Yale School of Medicine study found that PAT-DX1-NP administered by tail vein injection in a mouse model of triple-negative breast […]